Navigation Links
Dr. David Okrongly Appointed CEO of Quanterix Corporation
Date:9/2/2009

CAMBRIDGE, Mass., Sept. 2 /PRNewswire/ -- Quanterix Corporation, the leader in single molecule detection, announced today that David Okrongly, Ph.D. has been appointed Chief Executive Officer and a member of the company's Board of Directors. Dr. Okrongly replaces co-founder and interim CEO, Nicholas Naclerio, Ph.D., who will continue serving as Chairman of the Board.

Dr. Okrongly joins Quanterix from Siemens Healthcare Diagnostics Division, where he most recently served as Senior Vice President in charge of the Molecular Diagnostics business unit. In his 12 years at Siemens (formerly Bayer Healthcare), he led the worldwide introduction of a variety of novel chemical and immunochemical assays and multiple clinical diagnostic systems. Dr. Okrongly brings more than 20 years of experience in product development and commercialization, which includes previous senior management positions at Xytronyx and Applied Immune Sciences Inc.

"We are delighted to have recruited David as our CEO, and believe that his insight into the medical diagnostics area, strong technical background and commercial acumen are ideally suited to driving the next stages of growth at Quanterix as we continue efforts to develop assays and instrumentation that will permit the ultrasensitive detection of proteins implicated in various diseases," stated Chairman Nicholas Naclerio. "Furthermore, David brings to the company a demonstrated ability to translate diverse technologies into innovative products."

David Walt, Ph.D., Scientific Founder of Quanterix and Chair of the SAB added, "We are fortunate to have attracted an executive of Dr. Okrongly's caliber to lead Quanterix at this stage of the company's development. He brings an in-depth understanding of the diagnostics business and outstanding track record in the medical technology industry. We are very pleased to welcome David and look forward to his active participation and contributions to Quanterix's success."

Commenting on his new appointment, Dr. Okrongly said, "I am very excited to be joining a ground-breaking organization like Quanterix. A technology that enables unparalleled increases in analytical sensitivity will have significant applications in the diagnostics industry, allowing a variety of unmet medical needs to be addressed. I look forward to working with the current leadership team, employees and Board members as we continue to realize the full potential of this promising technology."

About Quanterix

Quanterix is developing a revolutionary Single Molecule Array (SiMoA(TM)) technology that allows the behavior of thousands of individual molecules to be observed simultaneously, rather than an ensemble average of many molecules as with existing technologies. Quanterix's platform will bring an unprecedented level of sensitivity, precision, and assay robustness to clinical diagnostics, drug development, and life science research. The first application that Quanterix is pursuing with the SiMoA(TM) technology is the detection and quantification of proteins present in blood and other body fluids at very low, previously undetectable, concentrations. Diagnostic assays targeting proteins that have been implicated in a variety of human diseases, including cancer, chronic inflammatory disease and neurological disorders are under development. Quanterix is a privately held company located in Cambridge, Massachusetts and is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures. For additional information, please visit www.quanterix.com.


'/>"/>
SOURCE Quanterix Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. WorldHeart Appoints David Pellone Chief Financial Officer
2. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
3. David Ward Joins OrthoSynetics(TM) as Western Region Sales Manager
4. The Law Offices of John David Hart: Texas Man Sues Medtronic in Body-Snatching Case
5. Mylan Announces Appointment of David A. Lillback as Senior Vice President and Global Head of Human Resources
6. St. Davids Medical Center Implements New Robotic Technology to Treat Common Heart Rhythm Disorders
7. David Grimes, FHI physician, inducted into Institute of Medicine
8. David Kahal Joins AXA Equitable as National Sales Manager
9. Leading Authority on Health Benefits, David Hom, Joins Board of Directors of Healthcare Technology Innovator, NavigatorMD, Inc.
10. Tree named in honor of Virginia Tech chemist David G.I. Kingston
11. David Luci Joins MacroChem as General Counsel and Vice President Corporate Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 27, 2016 , ... An educational campaign aimed at everyone ... courtesy of awareness-driven celebrities and thought leaders. It also provides insight to the ... leaders such as Bioness. , As patients feel increasingly concerned about the ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... Aimed at ... human interest stories, which come courtesy of leaders in the nursing and health care ... from leading advocates and associations—namely Abilene Christian University. , As the nursing industry ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are many ways to cook a ... (NHDSC) suggests that Americans prefer their dogs straight off the grill. Of the 90 ... their favorite way to cook a hot dog, far outpacing other cooking methods such ...
(Date:5/26/2016)... Atlanta, Georgia (PRWEB) , ... May 26, 2016 ... ... a certificate in intellectual property (IP) to its specialty academic programs. , Answering ... joins the college’s existing certificate programs in health law, and environmental and land ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... a significant negative impact on long-term patient survival, reports a team of UPMC ... online this week in the Journal of Thoracic and Cardiovascular Surgery, provide critical ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 2016 TARE (Transarterial Radio-embolization) ... Savings and Overall Decreased Use of Hospital ... international specialist healthcare company, has today announced the ... Meeting of ISPOR (International Society for Pharmacoeconomics and ... (HCC) using yttrium-90 glass microspheres is associated with ...
(Date:5/25/2016)... FDA 510(k) clearance covers ... for urological and surgical applications Mauna ... Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) platform, ... US with the 12 th 510(k) clearance ... This new FDA clearance covers Confocal Miniprobes indicated ...
(Date:5/25/2016)... , Germany and GERMANTOWN, ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... licensing and co-development agreement with Therawis Diagnostics GmbH to develop ... be to develop and market PITX2 as a marker to ... high-risk breast cancer patients. "We are pleased to ...
Breaking Medicine Technology: